Mechanism of CDK5/p25 binding by CDK inhibitors

Journal of Medicinal Chemistry

Volumn 48, Issue 3, 2005, Pages 671-679

  Mapelli, Marina ^a   Massimiliano, Lucia ^a   Crovace, Claudia ^a,b   Seeliger, Markus A ^c   Tsai, Li Huei ^d   Meijer, Laurent ^e   Musacchio, Andrea ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e STATION BIOLOGIQUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALOISINE; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE INHIBITOR; GLYCINE; PROTEIN P25; PROTEIN P35; ROSCOVITINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CRYSTAL; ENZYME REGULATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN STRUCTURE; REGULATORY MECHANISM; STEREOISOMERISM; STRUCTURE ANALYSIS;

CRYSTALLOGRAPHY, X-RAY; CYCLIN-DEPENDENT KINASE 5; CYCLIN-DEPENDENT KINASES; INDOLES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NERVE TISSUE PROTEINS; OXIMES; PROTEIN BINDING; PURINES; STEREOISOMERISM;

EID: 13444253813     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049323m     Document Type: Article

References (54)

1. Mapelli, M.; Musacchio, A. The structural perspective on CDK5. Neurosignals 2003, 12, 164-172.
2. Dhavan, R.; Tsai, L. H. A decade of CDK5. Nat. Rev. Mol. Cell. Biol. 2001, 2, 749-759.
3. Gupta, A.; Tsai, L. H. Cyclin-dependent kinase 5 and neuronal migration in the neocortex. Neurosignals 2003, 12, 173-179.
4. Ohshima, T.; Ward, J. M.; Huh, C. G.; Longenecker, G.; Veeranna; et al. Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc. Natl. Acad. Sci., U.S.A. 1996, 93, 11173-11178.
5. Gilmore, E. C.; Ohshima, T.; Goffinet, A. M.; Kulkarni, A. B.; Herrup, K. Cyclin-dependent kinase 5-deficient mice demonstrate novel developmental arrest in cerebral cortex. J. Neurosci. 1998, 18, 6370-6377.
6. Ko, J.; Humbert, S.; Bronson, R. T.; Takahashi, S.; Kulkarni, A. B.; et al. p35 and p39 are essential for cdk5 function during neurodevelopment. J. Neurosci. 2001, 21, 6758-6671.
7. Cheng, K.; Ip, N. Y. Cdk5: A new player at synapses. Neurosignals 2003, 12, 180-190.
8. Bibb, J. A. Role of cdk5 in neuronal signaling, plasticity, and drug abuse. Neurosignals 2003, 12, 191-199.
9. Nguyen, M. D.; Julien, J. P. Cyclin-dependent kinase 5 in amyotrophic lateral sclerosis. Neurosignals 2003, 12, 215-220.
10. Lau, L. F.; Ahlijanian, M. K. Role of CDK5 in the pathogenesis of Alzheimer's disease. Neurosignals 2003, 12, 209-214.
11. Smith, P. D.; Crocker, S. J.; Jackson-Lewis, V.; Jordan-Sciutto, K. L.; Hayley, S.; et al. Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci., U.S.A. 2003, 100, 13650-13655.
12. Bu, B.; Li, J.; Davies, P.; Vincent, I. Deregulation of CDK5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J. Neurosci. 2002, 22, 6515-6525.
13. Wang, J.; Liu, S.; Fu, Y.; Wang, J. H.; Lu, Y. CDK5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors. Nat. Neurosci. 2003, 6, 1039-1047.
14. Tarricone, C.; Dhavan, R.; Peng, J.; Areces, L. B.; Tsai, L.; et al. Structure and regulation of the CDK5-p25(nck5a) complex. Mol. Cell 2001, 8, 657-669.
15. Pavletich, N. P. Mechanisms of cyclin-dependent kinase regulation: structures of CDKs, their cyclin activators, and Cip and INK4 inhibitors. J. Mol. Biol. 1999, 287, 821-828.
16. Hisanaga, S.; Saito, T. The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 CDK5 activator. Neurosignals 2003, 12, 221-229.
17. Schulze-Gahmen, U.; Kim, S. H. Structural basis for CDK6 activation by a virus-encoded cyclin. Nat. Struct. Biol. 2002, 9, 177-181.
18. Zukerberg, L. R.; Patrick, G. N.; Nikolic, M.; Humbert, S.; Wu, C. L.; et al. Cables links CDK5 and c-Abl and facilitates CDK5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth. Neuron. 2000, 26, 633-646.
19. Patrick, G. N.; Zukerberg, L.; Nikolic, M.; de la Monte, S.; Dikkes, P.; et al. Conversion of p35 to p25 deregulates CDK5 activity and promotes neurodegeneration. Nature 1999, 402, 615-622.
20. Lau, L. F.; Seymour, P. A.; Sanner, M. A.; Schachter, J. B. CDK5 as a drug target for the treatment of Alzheimer's disease. J. Mol. Neurosci. 2002, 19, 267-273.
21. Sausville, E. A. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends. Mol. Med. 2002, 8, S32-37.
22. Fischer, L.; Endicott, J.; Meijer, L. Cyclin-dependent kinase inhibitors. In Cell Cycle Regulators as Therapeutic Targets; Meijer, L., Je'ze'quel, A., Roberge, M., Eds.; CNRS, Station Biologique de Roscoff: Roscoff, France, 2003; pp 235-248.
23. Knockaert, M.; Greengard, P.; Meijer, L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 2002, 23, 417-425.
24. Fischer, P. M.; Endicott, J.; Meijer, L. Cyclin-dependent kinase inhibitors. Prog. Cell Cycle Res. 2003, 5, 235-248.
25. Furet, P. X-ray crystallographic studies of CDK2, a basis for cyclin-dependent kinase inhibitor design in anti-cancer drug research. Curr. Med. Chem. Anti. Canc. Agents 2003, 3, 15-23.
26. Davies, T. G.; Pratt, D. J.; Endicott, J. A.; Johnson, L. N.; Noble, M. E. Structure-based design of cyclin-dependent kinase inhibitors. Pharmacol. Ther. 2002, 93, 125-133.
27. De Azevedo, W. F.; Leclerc, S.; Meijer, L.; Havlicek, L.; Strnad, M.; et al. Inhibition of cyclin-dependent kinases by purine analogues: Crystal structure of human CDK2 complexed with roscovitine. Eur. J. Biochem. 1997, 243, 518-526.
28. Meijer, L.; Kim, S. H. Chemical inhibitors of cyclin-dependent kinases. Methods Enzymol. 1997, 283, 113-128.
29. Meijer, L.; Raymond, E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc. Chem. Res. 2003, 36, 417-425.
30. Mettey, Y.; Gompel, M.; Thomas, V.; Garnier, M.; Leost, M.; et al. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J. Med. Chem. 2003, 46, 222-236.
31. Hoessel, R.; Leclerc, S.; Endicott, J. A.; Nobel, M. E.; Lawrie, A.; et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1999, 1, 60-67.
32. Meijer, L.; Skaltsounis, A. L.; Magiatis, P.; Polychronopoulos, P.; Knockaert, M.; et al. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem. Biol. 2003, 10, 1255-1266.
33. Polychronopoulos, P.; Magiatis, P.; Skaltsounis, A. L.; Myrianthopoulos, V.; Mikros, E.; et al. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J. Med. Chem. 2004, 47, 935-946.
34. Schulze-Gahmen, U.; Brandsen, J.; Jones, H. D.; Morgan, D. O.; Meijer, L.; et al. Multiple modes of ligand recognition: Crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins 1995, 22, 378-391.
35. De Azevedo, W. F.; Leclerc, S.; Meijer, L.; Havlicek, L.; Strnad, M.; et al. Inhibition of cyclin-dependent kinases by purine analogues: Crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 1997, 243, 518-526.
36. Gray, N. S.; Wodicka, L.; Thunnissen, A. M.; Norman, T. C.; Kwon, S.; et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 1998, 281, 533-538.
37. Davies, T. G.; Tunnah, P.; Meijer, L.; Marko, D.; Eisenbrand, G.; et al. Inhibitor binding to active and inactive CDK2: The crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Structure 2001, 9, 389-397.
38. Mettey, Y.; Gompel, M.; Thomas, V.; Garnier, M.; Leost, M.; et al. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J. Med. Chem. 2003, 46, 222-236.
39. Brown, N. R.; Noble, M. E.; Endicott, J. A.; Johnson, L. N. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat. Cell Biol. 1999, 1, 438-443.
40. Leclerc, S.; Garnier, M.; Hoessel, R.; Marko, D.; Bibb, J. A.; et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. 2001, 276, 251-260.
41. Filgueira de Azevedo, W., Jr.; Gaspar, R. T.; Canduri, F.; Camera, J. C., Jr.; Freitas da Silveira, N. J. Molecular model of cyclin-dependent kinase 5 complexed with roscovitine. Biochem. Biophys. Res. Commun. 2002, 297, 1154-1158.
42. Russo, A. A.; Jeffrey, P. D.; Pavletich, N. P. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat. Struct. Biol. 1996, 3, 696-700.
43. Jeffrey, P. D.; Russo, A. A.; Polyak, K.; Gibbs, E.; Hurwitz, J.; et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 1995, 376, 313-320.
44. Morgan, D. O. Principles of CDK regulation. Nature 1995, 374, 131-134.
45. Sasaki, Y.; Cheng, C.; Uchida, Y.; Nakajima, O.; Ohshima, T.; et al. Fyn and CDK5 mediate semaphorin-3A signaling, which is involved in regulation of dendrite orientation in cerebral cortex. Neuron 2002, 35, 907-920.
46. Schindler, T.; Bornmann, W.; Pellicena, P.; Miller, W. T.; Clarkson, B.; et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000, 289, 1938-1942.
47. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. In Macromolecular Crystallography, Part A; Academic Press: New York, 1997; pp 307-326.
48. Navaza, J. Implementation of molecular replacement in AMoRe. Acta Crystallogr, Sect. D: Biol. Crystallogr. 2001, 57, 1367-1372.
49. Lamzin, V. S.; Wilson, K. S. Automated Refinement for Protein Crystallography. Macromolecular Crystallography; Academic Press: New York, 1997; pp 269-305.
50. van Aalten, D. M. F.; Bywater, R.; Findlay, J. B. C.; Hendlich, M.; Hooft, R. W. W.; et al. PRODRG, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules. J. Comput.-Aided Mol. Des. 1996, 10, 255-262.
51. Brunger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1998, 54, 905-921.
52. Collaborative Computational Project, N. The CCP4 suite: Programs for protein crystallography. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1994, 50, 760-763.
53. Schindler, T.; Bornmann, W.; Pellicena, P.; Miller, W. T.; Clarkson, B.; et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000, 289, 1938-1942.
54. Wallace, A.; Laskowski, R.; Thornton, J. LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995, 8, 127-134.